Rapid and Sustained Efficacy of Subcutaneously Administered Cemdisiran Without Complete Complement Blockade in Patients with Generalized Myasthenia Gravis (gMG): Primary Efficacy and Safety Results from the Phase Three NIMBLE Trial (PL5.002)

Key Points

To evaluate the efficacy and safety of subcutaneously administered cemdisiran in patients with generalized myasthenia gravis.
Phase 3 NIMBLE trial (NCT05070858) design
Comparison of cemdisiran vs. placebo
Inclusion of patients with generalized myasthenia gravis
Cemdisiran demonstrated rapid efficacy with sustained effects in patients
Safety profile deemed acceptable, with adverse events reported
Significantly improved outcomes compared to placebo

Randomized trial compares cemdisiran with placebo in generalized myasthenia gravis, showing efficacy and safety outcomes.

Report on phase 3 NIMBLE trial (NCT05070858) comparing subcutaneous cemdisiran or pozelimab plus cemdisiran with placebo in patients with gMG.

No takes yet. Share an insight, caveat, or question.

Vu et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share